http://orcid.org/0000-0003-4808-9772
References
- CDER Manual of Policies and Procedures (MAPP) 6003. Silver Spring (MD): US Food and Drug Administration; 2014.
- Drug shortages summit. Bethesda (MD): American Society of Health-System Pharmacists; 2014.
- Friske E. Addressing looming prescription drug shortages through legislative and regulatory approaches. 14 Minn J.L. Sci & Tech. 2013;521:1.
- FDA. Developing products for rare diseases & conditions. Available from: http://www.fda.gov/forindustry/developingproductsforrarediseasesconditions/ucm2005525.htm
- Pollack A. Genzyme drug shortage leaves users feeling betrayed. in The New York Times. 2010.
- Liu H. Adopting solutions to orphan drug shortages. UC Davis Law Rev. 2015;48:2077.
- FDA drug shortages, current and resolved drug shortages and discontinuations reported to FDA. Available from: http://www.accessdata.fda.gov/scripts/drugshortages/
- American Society of Health-System Pharmacists, Drug shortage. Available from: http://www.ashp.org/menu/DrugShortages.
- Meekings KN, Williams CS, Arrowsmith JE. Orphan drug development: an economically viable strategy for biopharma R&D. Drug Discov Today. 2012;17(13–14):660–7. DOI:10.1016/j.drudis.2012.02.005
- Karst K. Orphan drug approvals dipped in 2015, while designations and designation requests continue upward trend. 2016; Available from: http://www.fdalawblog.net/fda_law_blog_hyman_phelps/2016/02/orphan-drug-approvals-dipped-in-2015-while-designations-and-designation-requests-continue-upward-tre.html
- Ventola CL. The drug shortage crisis in the United States: causes, impact, and management strategies. P T. 2011;36(11):740–757.
- FDA. A review of FDA’s approach to medical product shortages. Silver Spring (MD): US Food and Drug Administration; 2011.
- Subpart C—designation of an orphan drug. §316.25 Refusal to grant orphan-drug designation. Silver Spring (MD): US Food and Drug Administration; 2013.
- Greene N, Seoane-Vazquez E, Rodriguez-Monguio R, et al. Analysis of the prevalence of shortages of oncology drugs in the United States (2000-2014). PCN161. In: ISPOR 21st Annual International Meeting. Washington (DC): ISPOR; South Lawrenceville (NJ): International Society For Pharmacoeconomics and Outcomes Research;2016
- Barber J. Survey finds 83 percent of US oncologists faced cancer drug shortages. 2013 [ cited 29 Nov 2016]. Available from: http://www.firstwordpharma.com/node/1096300?tsid=33#axzz4RNUpxOIv
- Sharma A, Jacob A, Tandon M, et al. Orphan drug: Development trends and strategies. J Pharm Bioallied Sci. 2010;2(4):290–299. DOI:10.4103/0975-7406.72128
- FDA. Expedited programs: regulatory and quality implications for product development. Silver Spring (MD): US Food and Drug Administration; 2014. [cited 2016 Dec 15]. Available from: https://c.ymcdn.com/sites/www.casss.org/resource/resmgr/CMC_No_Am_Jan_Spkr_Slds/2014_CMCJan_AccDev_Lacana_Em.pdf
- Food and Drug Administration Safety and Innovation Act (FDASIA). Available from: http://www.fda.gov/RegulatoryInformation/Legislation/SignificantAmendmentstotheFDCAct/FDASIA/ucm20027187.htm
- Strategic plan for preventing and mitigating drug shortages. Silver Spring (MD): US Food and Drug Administration; 2013.
- Genzyme submits to $175M fine, FDA consent decree. 2010; Available from: www.fiercepharma.com/story/genzyme-submits-175m-fine-fda-consent-decree/2010-05-25
- 21 Code of Federal Regulations 316.36 - Insufficient quantities of orphan drugs. Available from: https://www.gpo.gov/fdsys/granule/CFR-2014-title21-vol5/CFR-2014-title21-vol5-sec316-36
- Hoffman S. The drugs stop here: a public health framework to address the drug shortage crisis. Food Drug L J. 2012;67(1):14–16.